Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Cardiology

  • 1
    News

    SGLT2 inhibitor use rising in patients with DKD

    August 23, 2021

    Use of SGLT2 inhibitors in patients with type 2 diabetes rose sharply in 2019 and early 2020. GLP-1 RA use also showed recent gains.

  • 1
    News

    Apixaban more effective, safer than rivaroxaban for Afib patients

    August 23, 2021

    Is apixaban more effective and safer than rivaroxaban in patients with atrial fibrillation?

  • News

    Empagliflozin gets HFrEF approval from FDA

    August 19, 2021

    The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.

  • 1
    News

    Use of point-of-care ultrasound (POCUS) for heart failure

    August 16, 2021

    Hospitalist use of POCUS may include guiding procedures, aiding in diagnosis, and assessing effectiveness of treatment.

  • 1
    News

    Heparin’s COVID-19 benefit greatest in moderately ill patients

    August 13, 2021

    A multiplatform trial reported that therapeutic heparin improved outcomes in moderately ill COVID-19 patients but not in critically ill patients.

  • News

    Tachycardia syndrome may be distinct marker for long COVID

    August 13, 2021

    Post-COVID patients with palpitations or chest pain should undergo a cardiac workup, new research suggests. The data also shed light on potential treatments.

  • News

    Docs fight back after losing hospital privileges, patients, and income

    August 10, 2021

    Physicians in St. Louis lost their hospital privileges when the hospital entered into an exclusive contract with other physicians. They’re losing patients and money.

  • 1
    News

    Myocarditis tied to COVID-19 shots more common than reported?

    August 6, 2021

    Myocarditis may develop rapidly in younger people, mostly after the second dose, while pericarditis affects older adults after the first or second dose. Both remain rare, new results show.

  • News

    DOACs best aspirin after ventricular ablation: STROKE-VT

    August 2, 2021

    Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.

  • 1
    News

    ESC heart failure guideline to integrate bounty of new meds

    July 29, 2021

    It has a simple answer to a seemingly complex issue: how to merge the newly approved with mainstay drug therapies. And it conditionally okays meds in a group long without guideline-directed options.

Previous1 … 9 10 11 12 13 … 79Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences